Commit Biologics

๐Ÿ“‚ Healthtech๐Ÿ“ Copenhagen๐Ÿ—“๏ธ Founded: 2021

Copenhagen biotech spun out of Aarhus University, developing the BiCE platform for oncology and autoimmune diseases.

Europe's most interesting startup stories. Every week.

No spam. Unsubscribe anytime.

Podcast Episode

๐ŸŽ™๏ธ Deep Dive

Payhawk, Commit Biologics, Dcubed โ€” $280M for AI finance, immunotherapy and space hardware โ€” Daily News November 18, 2026

Listen to the episode

About Commit Biologics

Commit Biologics is a Copenhagen biotech spun out of Aarhus University and initially incubated by the BioInnovation Institute. It develops Bispecific Complement Engagers (BiCE), antibodies designed to recruit the complement system, part of innate immunity, against target cells. Its first candidate, COM002, is a dual-targeting molecule for targeted immune cell depletion in patients with cancer and autoimmune disease. Launched in May 2024 with a โ‚ฌ16 million seed backed by Novo Holdings and Bioqube Ventures, on 17 November 2026 it completed a $60 million (โ‚ฌ54 million) seed financing led by Ackermans & van Haaren, with AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. The money will fund IND-enabling work and the IND filing for COM002, with first patient dosing expected in early 2028, plus a second programme. Its CEO is Thomas L. F. Montgomery Andresen, who joined from T-Cypher Bio in 2026.

The Story

Spun out of Aarhus University, incorporated in 2021 as Commit Biologics ApS and incubated by the BioInnovation Institute; publicly launched in May 2024 with a โ‚ฌ16 million seed round.

How Commit Biologics works

Business Model

Biologic drug development, with potential pharmaceutical partnerships.

Products & Services

Key Products

  • BiCE platform
  • COM002

Core Use Cases

  • Oncology
  • Autoimmune diseases
  • Targeted immune cell depletion

Market & Clients

Key Customers

Patients and, in future, pharmaceutical partners.

Geographic Presence

DK

How Commit Biologics competes

Competitive Advantages

  • Targeted complement activation through bispecific antibodies

How Commit Biologics grows

Growth Strategy

Take COM002 to an IND filing and into the clinic and advance a second programme.

Regulatory Context

COM002 must complete IND-enabling work and an IND filing before clinical trials.

Key Risks

  • Clinical risk
  • Regulatory risk
  • Safety and efficacy not yet shown in humans

Strategic Insights

  • The round funds the move from a preclinical platform towards the clinic, bringing in two pharma corporate venture investors.

Funding & Investors

Funding Rounds

  • 2026 - Seed (final close): $60M (โ‚ฌ54M)
    Lead: Ackermans & van Haaren
  • 2024 - Seed: โ‚ฌ16M

Key Investors

Ackermans & van HaarenNovo HoldingsBioqube VenturesKorysAbbVie VenturesM Ventures

Founding Team

Key Executives

  • Thomas L. F. Montgomery Andresen - CEO

Key Metrics

Prima somministrazione ai pazienti attesainizio 2028 (2026)

Lessons from Commit Biologics

  • A scientific platform becomes investable when it produces candidates and measurable regulatory milestones.

Similar Startups

๐Ÿ“ Copenhagen

Teton.ai

Copenhagen company founded in 2020 with AI for care facilities. On 9 September 2025 it announced a $20 million Series A.

Read Analysis
๐Ÿ“ Copenhagen

Adcendo

A clinical-stage Copenhagen biotech developing antibody-drug conjugates (ADCs) for cancers with high unmet need, with three programmes in the clinic.

Read Analysis
๐Ÿ“ Amsterdam

NewAmsterdam Pharma

Biopharmaceutical company focused on innovative therapies for hypercholesterolemia and cardiometabolic diseases with breakthrough clinical results.

Read Analysis

Sources

๐ŸŽ™๏ธ Scalable Podcast โ€” European startup stories ยท ๐Ÿ‡ฎ๐Ÿ‡น in Italian
Spotify ๐ŸŽง Apple